Pfizer to spend $120 million to boost U.S. COVID pill manufacturing

Published: Jun 6, 2022, 15:38 UTC1min read
(Reuters) – Pfizer Inc said on Monday it would spend $120 million to expand manufacturing of its COVID-19 antiviral treatment at its Michigan plant, as demand ramps up.
Most Popular

(Reuters) – Pfizer Inc said on Monday it would spend $120 million to expand manufacturing of its COVID-19 antiviral treatment at its Michigan plant, as demand ramps up.

Use of the pill, Paxlovid, authorized to treat newly infected, at-risk people to prevent severe illness, has soared recently as infections rise.

Advertisement
Know where Markets is headed? Take advantage now with

Your capital is at risk

Biden administration officials have pushed for the wider use of Paxlovid, which the government distributes for free.

(Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)

Don't miss a thing! Sign up for a daily update delivered to your inbox

Latest Articles

See All